Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in Mice

International Journal of Neuropsychopharmacology

Volumn 18, Issue 5, 2015, Pages 1-10

  Gomes, Felipe V ^a   Issy, Ana Carolina ^a   Ferreira, Frederico R ^b   Viveros, Maria Paz ^c   Del Bel, Elaine A ^a   Guimaraes, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Antipsychotic; Cannabidiol; Cannabinoid; Clozapine; NMDA receptor hypofunction; Schizophrenia

Indexed keywords

CANNABIDIOL; CLOZAPINE; DIZOCILPINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NMDAR GLUN1 SUBUNIT GENE PROTEIN; PARVALBUMIN; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; DIZOCILPINE MALEATE; FOSB PROTEIN, MOUSE; GPRIN1 PROTEIN, MOUSE; NERVE PROTEIN; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN FUNCTION; BRAIN REGION; BRAIN SLICE; CHRONIC DRUG ADMINISTRATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG REEXPOSURE; HIPPOCAMPUS; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PREPULSE INHIBITION; PREPULSE INHIBITION DISRUPTION TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REPEATED DRUG DOSE; SCHIZOPHRENIA; SENSORY GATING; SINGLE DRUG DOSE; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PREFRONTAL CORTEX; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; CANNABIDIOL; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; GABAERGIC NEURONS; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; PARVALBUMINS; PREFRONTAL CORTEX; PREPULSE INHIBITION; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA; SENSORY GATING; TREATMENT OUTCOME;

EID: 84929276214     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu041     Document Type: Article

References (77)

1. Abdul-Monim, Z, Neill, JC, Reynolds, GP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21(2):198-205.
2. Adams, B, Moghaddam, B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18(14):5545-5554.
3. Amitai, N, Kuczenski, R, Behrens, MM, Markou, A (2012) Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology 62(3):1422-1431.
4. Atkins, JB, Chlan-Fourney, J, Nye, HE, Hiroi, N, Carlezon, WA, Jr., Nestler, EJ (1999) Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs. Synapse 33(2):118-128.
5. Behrens, MM, Ali, SS, Dao, DN, Lucero, J, Shekhtman, G, Quick, KL, Dugan, LL (2007) Ketamine-induced loss of phenotype of fastspiking interneurons is mediated by NADPH-oxidase. Science 318(5856):1645-1647.
6. Belforte, JE, Zsiros, V, Sklar, ER, Jiang, Z, Yu, G, Li, Y, Quinlan, EM, Nakazawa, K (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13(1):76-83.
7. Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, Martin-Santos, R, Borgwardt, S, Winton-Brown, T, Nosarti, C, O'Carroll, CM, Seal, M, Allen, P, Mehta, MA, Stone, JM, Tunstall, N, Giampietro, V, Kapur, S, Murray, RM, Zuardi, AW, Crippa, JA, Atakan, Z, McGuire, PK (2010) Opposite effects of delta- 9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3):764-774.
8. Blumenthal, TD (1996) Inhibition of the human startle response is affected by both prepulse intensity and eliciting stimulus intensity. Biol Psychology 44(2):85-104.
9. Blumenthal, TD, Levey, BJ (1989) Prepulse rise time and startle reflex modification: Different effects for discrete and continuous prepulses. Psychophysiology 26(2):158-165.
10. Braff, DL, Geyer, MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47(2):181-188.
11. Braff, DL, Geyer, MA, Light, GA, Sprock, J, Perry, W, Cadenhead, KS, Swerdlow, NR (2001) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49(1-2):171-178.
12. Braff, DL, Geyer, MA, Swerdlow, NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156(2-3):234-258.
13. Breier, A, Malhotra, AK, Pinals, DA, Weisenfeld, NI, Pickar, D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psych 154(6):805-811.
14. Bubenikova-Valesova, V, Horacek, J, Vrajova, M, Hoschl, C (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32(5):1014-1023.
15. Campos, AC, Moreira, FA, Gomes, FV, Del Bel, EA, Guimaraes, FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc B 367(1607):3364-3378.
16. Casarotto, PC, Gomes, FV, Resstel, LB, Guimaraes, FS (2010) Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol 21(4):353-358.
17. Cochran, SM, Kennedy, M, McKerchar, CE, Steward, LJ, Pratt, JA, Morris, BJ (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28(2):265-275.
18. Dietz, DM, Kennedy, PJ, Sun, H, Maze, I, Gancarz, AM, Vialou, V, Koo, JW, Mouzon, E, Ghose, S, Tamminga, CA, Nestler, EJ (2014) DeltaFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes. Neuropsychopharmacology 39(3):538-544.
19. Duncan, GE, Leipzig, JN, Mailman, RB, Lieberman, JA (1998) Differential effects of clozapine and haloperidol on ketamineinduced brain metabolic activation. Brain Res 812(1-2):65-75.
20. Elhardt, M, Martinez, L, Tejada-Simon, MV (2010) Neurochemical, behavioral and architectural changes after chronic inactivation of NMDA receptors in mice. Neurosci Lett 468(2):166-171.
21. Franklin KBJ, Paxinos G (2008). The mouse brain in stereotaxic coordinates, 3th ed. New York: Academic Press.
22. Gao, XM, Sakai, K, Roberts, RC, Conley, RR, Dean, B, Tamminga, CA (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psych 157(7):1141-1149.
23. Geyer, MA, Krebs-Thomson, K, Braff, DL, Swerdlow, NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156(2-3):117-154.
24. Gonzalez-Burgos, G, Lewis, DA (2012) NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull 38(5):950-957.
25. Graham, FK (1975) The more or less startling effects of weak prestimulation. Psychophysiology 12(3):238-248.
26. Grande, C, Zhu, H, Martin, AB, Lee, M, Ortiz, O, Hiroi, N, Moratalla, R (2004) Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry 55(5):457-463.
27. Guidali, C, Vigano, D, Petrosino, S, Zamberletti, E, Realini, N, Binelli, G, Rubino, T, Di Marzo, V, Parolaro, D (2011) Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int J Neuropsychopharmacology 14(1):17-28.
28. Guimaraes, VM, Zuardi, AW, Del Bel, EA, Guimaraes, FS (2004) Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 75(5):633-638.
29. Gururajan, A, Taylor, DA, Malone, DT (2011) Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav Brain Res 222(2):299-308.
30. Gururajan, A, Taylor, DA, Malone, DT (2012). Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. J Psychopharmacol 26(10):1317-1332.
31. Harte, MK, Powell, SB, Swerdlow, NR, Geyer, MA, Reynolds, GP (2007) Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm 114(7):893-898.
32. Hashimoto, T, Volk, DW, Eggan, SM, Mirnics, K, Pierri, JN, Sun, Z, Sampson, AR, Lewis, DA (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23(15):6315-6326.
33. Issy, AC, Salum, C, Del Bel, EA (2009) Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice. Behav Brain Res 205(2):475-481.
34. Javitt, DC, Zukin, SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psych 148(10):1301-1308.
35. Jentsch, JD, Roth, RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3):201-225.
36. Jodo, E, Suzuki, Y, Katayama, T, Hoshino, KY, Takeuchi, S, Niwa, S, Kayama, Y (2005) Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb Cortex 15(5):663-669.
37. Kontkanen, O, Lakso, M, Wong, G, Castren, E (2002) Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology 27(2):152-162.
38. Krystal, JH, Karper, LP, Seibyl, JP, Freeman, GK, Delaney, R, Bremner, JD, Heninger, GR, Bowers, MB, Jr., Charney, DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199-214.
39. Krystal, JH, D'Souza, DC, Mathalon, D, Perry, E, Belger, A, Hoffman, R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169(3-4):215-233.
40. Krystal, JH, Perry, EB, Jr., Gueorguieva, R, Belger, A, Madonick, SH, Abi-Dargham, A, Cooper, TB, Macdougall, L, Abi-Saab, W, D'Souza, DC (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62(9):985-994.
41. Lahti, AC, Holcomb, HH, Medoff, DR, Tamminga, CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6(6):869-872.
42. Lane, SJ, Ornitz, EM, Guthrie, D (1991) Modulatory influence of continuous tone, tone offset, and tone onset on the human acoustic startle response. Psychophysiology 28(5):579-587.
43. Larrauri J, Schmajuk N (2006) Prepulse inhibition mechanisms and cognitive processes: a review and model. EXS 98:245-278.
44. Law, AJ, Deakin, JF (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12(13):2971-2974.
45. Levin, R, Peres, FF, Almeida, V, Calzavara, MB, Zuardi, AW, Hallak, JE, Crippa, JA, Abilio, VC (2014) Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. Front Pharmacol 5:10.
46. Leweke, FM, Piomelli, D, Pahlisch, F, Muhl, D, Gerth, CW, Hoyer, C, Klosterkotter, J, Hellmich, M, Koethe, D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94.
47. Lewis, DA, Hashimoto, T, Volk, DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6(4):312-324.
48. Lisman, JE, Coyle, JT, Green, RW, Javitt, DC, Benes, FM, Heckers, S, Grace, AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31(5):234-242.
49. Lobo, MK, et al. (2013) DeltaFosB Induction in Striatal Medium Spiny Neuron Subtypes in Response to Chronic Pharmacological, Emotional, and Optogenetic Stimuli. J Neurosci 33(47):18381-18395.
50. Long, LE, Malone, DT, Taylor, DA (2006) Cannabidiol reverses MK- 801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31(4):795-803.
51. Long, LE, Chesworth, R, Huang, XF, Wong, A, Spiro, A, McGregor, IS, Arnold, JC, Karl T (2012) Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLOS ONE 7(4):e34129.
52. Martinez, ZA, Ellison, GD, Geyer, MA, Swerdlow, NR (1999) Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21(1):28-39.
53. Moghaddam, B, Adams, B, Verma, A, Daly, D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921-2927.
54. Moreau, AW, Kullmann, DM (2013) NMDA receptor-dependent function and plasticity in inhibitory circuits. Neuropharmacology 74:23-31.
55. Moreira, FA, Guimaraes, FS (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512(2-3):199-205.
56. Morrow, BA, Elsworth, JD, Roth, RH (2007) Repeated phencyclidine in monkeys results in loss of parvalbumin-containing axo-axonic projections in the prefrontal cortex. Psychopharmacology (Berl) 192(2):283-290.
57. Nestler, EJ, Kelz, MB, Chen, J (1999) DeltaFosB: a molecular mediator of long-term neural and behavioral plasticity. Brain Res 835(1):10-17.
58. Olney, JW, Farber, NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52(12):998-1007.
59. Penschuck, S, Flagstad, P, Didriksen, M, Leist, M, Michael-Titus, AT (2006) Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci 23(1):279-284.
60. Pilowsky, LS, Bressan, RA, Stone, JM, Erlandsson, K, Mulligan, RS, Krystal, JH, Ell, PJ (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11(2):118-119.
61. Reynolds, GP, Beasley, CL, Zhang, ZJ (2002) Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J Neural Transm 109(5-6):881-889.
62. Rodriguez, JJ, Garcia, DR, Nakabeppu, Y, Pickel, VM (2001) Enhancement of laminar FosB expression in frontal cortex of rats receiving long chronic clozapine administration. Exp Neurol 168(2):392-401.
63. Rujescu, D, Bender, A, Keck, M, Hartmann, AM, Ohl, F, Raeder, H, Giegling, I, Genius, J, McCarley, RW, Moller, HJ, Grunze, H (2006) A pharmacological model for psychosis based on N-methyl-Daspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 59(8):721-729.
64. Schwartz, TL, Sachdeva, S, Stahl, SM (2012) Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 3:195.
65. Swerdlow, NR, Braff, DL, Geyer, MA (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 11(3-4):185-204.
66. Swerdlow, NR, Geyer, MA, Braff, DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194-215.
67. Swerdlow, NR, Stephany, N, Wasserman, LC, Talledo, J, Shoemaker, J, Auerbach, PP (2003) Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology 28(4):640-650.
68. Swerdlow, NR, Blumenthal, TD, Sutherland, AN, Weber, E, Talledo, JA (2007) Effects of prepulse intensity, duration, and bandwidth on perceived intensity of startling acoustic stimuli. Biol Psychology 74:389-395.
69. Todtenkopf, MS, Stellar, JR, Williams, EA, Zahm, DS (2004) Differential distribution of parvalbumin immunoreactive neurons in the striatum of cocaine sensitized rats. Neuroscience 127(1):35-42.
70. Vigano, D, Guidali, C, Petrosino, S, Realini, N, Rubino, T, Di Marzo, V, Parolaro, D (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychop 12(5):599-614.
71. Wang, HD, Takigawa, M, Hamada, K, Shiratani, T, Takenouchi, K, Wang, G (2000) Reciprocal information flow between prefrontal cortex and ventral tegmental area in an animal model of schizophrenia. Neuroreport 11(9):2007-2011.
72. Weickert, CS, Fung, SJ, Catts, VS, Schofield, PR, Allen, KM, Moore, LT, Newell, KA, Pellen, D, Huang, XF, Catts, SV, Weickert, TW (2013) Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry 18(11):1185-1192.
73. Yee, BK, Chang, T, Pietropaolo, S, Feldon, J (2005) The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behav Brain Res 163(2):265-276.
74. Zuardi, AW, Shirakawa, I, Finkelfarb, E, Karniol, IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76(3):245-250.
75. Zuardi, AW, Rodrigues, JA, Cunha, JM (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 104(2):260-264.
76. Zuardi, AW, Morais, SL, Guimaraes, FS, Mechoulam, R (1995) Antipsychotic Effect of Cannabidiol. J Clin Psychiatry 56(10):485-486.
77. Zuardi, AW, Hallak, JE, Dursun, SM, Morais, SL, Sanches, RF, Musty, RE, Crippa, JA (2006) Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20(5):683-686.